DNA’s 39th Annual Convention Schedule
Thursday, April 22, 2021
8:00 am – 9:00 am EST
9:00 am – 10:00 am EST
General Session 201
Topic/Title: The Art of Diagnosis and Management of Dermatologic Disease in Skin of Color
We will discuss the impact on accurate diagnosis in skin of color. Skin color matters and the importance of recognizing early erythema will save lives.
Speaker: Lynn McKinley-Grant, MD
10:00 am – 10:30 am EST
10:30 am – 11:30 am EST
General Session 211
Topic/Title: New Txs/Meds/JAK Inhibitors/Clinical Trials
JAK inhibitors are small molecules with huge promise in Dermatology. In this lecture, we will discuss the mechanism of JAK inhibitors, identify the current FDA approved indications of JAK inhibitors, and explore future uses of JAK inhibitors in Dermatology.
Speaker: Aaron Mangold, MD, FAAD
11:30 am – 11:45 am EST
11:45 am – 12:45 pm EST
General Session 221
Topic/Title: Teledermatology; Maintain Quality of Care and Patient Satisfaction in a Virtual Visit
Virtual visits were already becoming more widely used in health care as a means to expand access to care. The advent of the COVID-19 pandemic pushed the discipline into the essential range. To facilitate continuity of care and limit exposure, many dermatology offices launched Teledermatology programs. This lecture looks at existing and emerging research on successful implementation, evaluation, and maintenance of Teledermatology in practice. We will also review available literature looking at health outcomes and patient satisfaction.
Speaker: Katrina Nice Masterson, DNP, RN, FNP-BC, DCNP
12:45 pm – 1:00 pm EST
1:00 pm – 2:00 pm EST
General Session 231
Product Theater: Studies in Clearance – Skyrizi for Moderate-to-Severe Plaque Psoriasis
Sponsored by AbbVie Inc. No CE
Speaker: Lakshi Aldredge, MSN, ANP-BC, DCNP
2:00 pm – 2:15 pm EST
2:15 pm – 3:15 pm EST
General Session 241
Topic/Title: Quality of Life in Cutaneous Lymphoma Patients and Families: Emerging Results and Conclusions
This presentation will explore the quality of life issues faced by cutaneous lymphoma patients and their families through the analysis of research findings in this arena. The implications for nursing practice in caring for these patients and families are also identified.
Sue McCann, MSN, RN, DNC
Marianne Tawa, MSN, RN, CRNP
Susan Thornton, BS
3:15 pm – 3:45 pm EST
3:45 pm – 4:45 pm EST
General Session 251
Topic/Title: A Nurse’s Journey with Pemphigus Vulgaris
Pemphigus and pemphigoid (P/P) are chronic, autoimmune, blistering diseases that target proteins essential in holding together skin and mucosal epithelial cells. The average patient has to see 5 healthcare professionals over the course of 10 months to receive a correct diagnosis. Due to the high prevalence of patients’ oral symptoms, dental practitioners have the unique opportunity to reduce diagnostic delays.
Speaker: Becky Strong, BS, RN
4:45 pm – 5:00 pm EST
5:00 pm – 6:00 pm EST
General Session 261
Topic/Title: Robin Weber Immunology Symposium: Modern Management of Hidradenitis Suppurativa
For a busy clinic, how can we do our best for patients with Hidradenitis Suppurativa (HS)? What new knowledge can you gain and put into practice to help improve patients’ lives? We’ll discuss the latest advances in HS management and which treatments get used for which patient. You’ll get a list of the top management recommendations for HS that you can use right away!
Speaker: Joslyn Kirby, MD, MS